Top news of the week: 02.02.2022.
Companies And Industries
Life Sciences Companies Leverage New Partnerships Against Severe Diseases
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
As CEO goes, cash woes drive Sio to give Parkinson's program the heave-ho
Sio Gene Therapies is dumping its midphase Parkinson’s disease program to eke out its cash into 2023. Years after the biotech, then known as Axovant, had a high-profile failure in ...
Biopharma money raised: Jan. 1-27, 2022
Year-to-date money raised in public, private and other financings of biopharma companies.
Listen: Janet Woodcock on Covid antibodies, vaccines for kids, and responding to Omicron
Who gets to be an "expert" on Covid-19? Are Americans entitled to drugs that don't work? And how does the FDA deal with states' rights? Find out on the latest episode of "The Readout LOUD." ...
From Zero to Hero: Biopharma's Pivotal Inflection Point
Some might go as far as to consider the pharmaceutical industry as mankind’s best hope for survival. But now, as the world enters the third year of the pandemic, has that perception changed?
Daiichi makes play for share of Japan’s COVID booster market
Japan's Daiichi Sankyo makes a late play for the COVID-19 booster shot market, starting a combined phase 1/2/3 trial of its DS-5670 candidate – but can it catch Pfizer/BioNTech and Moderna?
Glowing yeast lights the way to better biofuels
Advanced biofuels could play a key role in curbing emissions and mitigating climate change, but choosing the right yeast for production is slow and arduous. A new tool from Princeton ...
Ingmar Hoerr
Listen to Ingmar Hoerr from First Rounders. Ingmar Hoerr is a co-founder and former CEO of CureVac. His conversation with Nature Biotechnology covers his initial discovery with RNA while in ...